Evidence map›Paper›PMID 35956423›Full record

ArticleNutrients2022

Supplementation of

Dou-Dou Li, Jia-Min Ma, Ming-Jing Li, Lu-Lu Gao, Yan-Na Fan, Yan-Nan Zhang, Xiu-Juan Tao, Jian-Jun Yang

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Multi-Target Cardioprotection fromAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Frontiers in pharmacology · 2026
    Article
  7. Article
  8. [Curcumin inhibits lipid metabolism in non-small cell lung cancer by downregulating the HIF-1α pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  9. Review
  10. Food science & nutrition · 2025
    Article
  11. Dietary supplementation ofAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2025
    Article
  12. Regulatory effects ofFrontiers in immunology · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. DietaryAntioxidants (Basel, Switzerland) · 2024
    Article
  18. Review
  19. Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Dou-Dou LiSchool of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China.
Jia-Min MaYuyang District Center for Disease Control and Prevention, Yulin 719000, China.
Ming-Jing LiSchool of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China.
Lu-Lu GaoSchool of Public Health, Xinxiang Medical University, Xinxiang 453003, China.
Yan-Na FanSchool of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China.
Yan-Nan ZhangSchool of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China.
Xiu-Juan TaoSchool of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China.
Jian-Jun YangSchool of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China.
Ningxia Medical University · CNChinese Center For Disease Control and Prevention · CNNingxia Center for Diseases Prevention and Control · CNXinxiang Medical University · CN

Funding

key research project of Ningxia 2021BEG03031National Natural Science Foundation of China 82060597
6 · The paper itself

Abstract

Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease (NAFLD). Either

Indexed as

Non-alcoholic Fatty Liver DiseaseAMP-Activated Protein KinasesAnimalsDietary SupplementsDrugs, Chinese HerbalFatty AcidsLipidsLiverPPAR alphaRatsRats, Sprague-DawleyAMP-Activated Protein KinasesDrugs, Chinese HerbalFatty AcidsLipidslycium barbarum polysaccharidePPAR alphaaerobic exercisefatty acid oxidationLycium barbarum polysaccharidenonalcoholic steatohepatitis

Identifiers

PMID35956423
PMCPMC9370707
OpenAlexW4292452335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.